Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ropivacaine HCL
Ropivacaine · 1 trial · 3 indications
Assess pain intensity (evaluated by NRS) after surgery on the as response to the prompt: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?" The AUC will be derived for each participant from self-reported pain scores and will be summarized by treatment group. Generalized linear models with main effect of treatment will be estimated to test for significant differences in AUC between the arms.
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Intraoperative R.E.C.K. |
| Arm B | EXPERIMENTAL | Intraoperative Exparel |
| Name | Type | Description |
|---|---|---|
| Ropivacaine HCL | DRUG | 123 mg, intramuscular |
| Exparel | DRUG | 100 mL total dose - Intramuscular (IM), intraoperatively |
| Epinephrine | DRUG | 0.25 mg, intramuscular |
| Clonidine HCL | DRUG | 0.04 mg, intramuscular |
| Ketorolac | DRUG | 15 mg, intramuscular |
Inclusion Criteria: 1. Ability to understand and willingness to sign an IRB-approved informed consent 2. Age ≥ 18 years at the time of consent. 3. Planned robotic partial or radical nephrectomy Exclusion Criteria: 1. Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling...
Ropivacaine is an investigational small molecule being studied for pain management in patients with Renal Carcinoma undergoing robotic nephrectomy. It is in a Phase 3 clinical trial that compares it to Exparel, an active control, to evaluate its effectiveness in managing pain after the surgical procedure.
Ropivacaine is a local anesthetic that works by blocking nerve signals in the area where it is administered, providing pain relief. In the context of the Phase 3 trial, it is used locally to manage postoperative pain in patients with Renal Carcinoma after robotic nephrectomy.
Ropivacaine is being developed by Atrium Therapeutics, Inc., a company listed under the ticker RNA. The company is conducting a Phase 3 clinical trial to evaluate the drug for pain management in Renal Carcinoma patients undergoing robotic nephrectomy.
Ropivacaine is currently in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied in a randomized, active-controlled trial for pain management in Renal Carcinoma patients undergoing robotic nephrectomy.
Ropivacaine is being studied in a Phase 3 clinical trial with the identifier NCT07092566, titled 'R.E.C.K vs Exparel in Robotic Nephrectomy'. This trial is recruiting 170 participants in the United States and is evaluating the drug for pain management in Renal Carcinoma patients.
Yes, Ropivacaine is also known as Ropivacaine HCL. Both names refer to the same investigational drug being developed by Atrium Therapeutics, Inc. for pain management in Renal Carcinoma patients undergoing robotic nephrectomy.